ExpreS2ion to present in upcoming investor and scientific events
Hørsholm, Denmark, 18 November 2024 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in upcoming investor and scientific events, including the BioStock Life Science Summit, the Immunotherapies and Innovations for Infectious Diseases Congress and Aktiespararna’s Stora Aktiedagen.
By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website and via the links below.
21 November 2024 | BioStock Life Science Summit
Lund, Sweden
The BioStock Life Science Summit is a Nordic meeting place for entrepreneurs, industry and investors, and offers a peek into the future of biotech, pharma, diagnostics and health care devices. On November 21, CEO Bent Frandsen will present. To schedule a meeting, please contact us via email on info@expreS2ionbio.com. More information is available on the BioStock website.
27-28 November 2024 | Immunotherapies and Innovations for Infectious Diseases (I4ID) Congress
Lyon, France
The purpose of this congress is to foster interactions between pharmaceutical industries, research labs, service providers, technology developers, and clinicians, thereby contributing to the development of innovative strategies against infectious diseases in a multidisciplinary approach. CSO Farshad Guirakhoo will represent ExpreS2ion. To schedule a meeting, please contact us via email on info@expreS2ionbio.com. More information is available on the I4ID website.
27 November 2024 | Aktiespararna Stora Aktiedagen
Stockholm, Sweden
Join us for a live update from our CEO Bent Frandsen at 14:45 on Wednesday, November 27 at Aktiespararna’s Stora Aktiedagen in Stockholm. The event can be streamed through Aktiespararna’s YouTube channel or directly from their website at aktiespararna.se/tv/live. To register for the event, please go to Aktiesparana’s event page.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.